Close Menu

NEW YORK – A group of researchers at the University of Texas MD Anderson Cancer Center has applied a blood-based circulating tumor cell (CTC) assay to potentially predict relapse in stage III melanoma cancer patients.

The team plans to develop a combined assay that integrates both CTCs and circulating tumor DNA (ctDNA) to potentially eliminate the need for repeated positron emission tomography (PET) image surveillance for melanoma patients at risk of recurrence.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Sponsored by

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.